quetiapine-fumarate and Sleep-Apnea-Syndromes

quetiapine-fumarate has been researched along with Sleep-Apnea-Syndromes* in 2 studies

Reviews

1 review(s) available for quetiapine-fumarate and Sleep-Apnea-Syndromes

ArticleYear
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
    Alcohol (Fayetteville, N.Y.), 2015, Volume: 49, Issue:4

    Insomnia in patients with alcohol dependence has increasingly become a target of treatment due to its prevalence, persistence, and associations with relapse and suicidal thoughts, as well as randomized controlled studies demonstrating efficacy with behavior therapies and non-addictive medications. This article focuses on assessing and treating insomnia that persists despite 4 or more weeks of sobriety in alcohol-dependent adults. Selecting among the various options for treatment follows a comprehensive assessment of insomnia and its multifactorial causes. In addition to chronic, heavy alcohol consumption and its effects on sleep regulatory systems, contributing factors include premorbid insomnia; co-occurring medical, psychiatric, and other sleep disorders; use of other substances and medications; stress; environmental factors; and inadequate sleep hygiene. The assessment makes use of history, rating scales, and sleep diaries as well as physical, mental status, and laboratory examinations to rule out these factors. Polysomnography is indicated when another sleep disorder is suspected, such as sleep apnea or periodic limb movement disorder, or when insomnia is resistant to treatment. Sobriety remains a necessary, first-line treatment for insomnia, and most patients will have some improvement. If insomnia-specific treatment is needed, then brief behavioral therapies are the treatment of choice, because they have shown long-lasting benefit without worsening of drinking outcomes. Medications work faster, but they generally work only as long as they are taken. Melatonin agonists; sedating antidepressants, anticonvulsants, and antipsychotics; and benzodiazepine receptor agonists each have their benefits and risks, which must be weighed and monitored to optimize outcomes. Some relapse prevention medications may also have sleep-promoting activity. Although it is assumed that treatment for insomnia will help prevent relapse, this has not been firmly established. Therefore, insomnia and alcohol dependence might be best thought of as co-occurring disorders, each of which requires its own treatment.

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Dyssomnias; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Polysomnography; Quetiapine Fumarate; Sleep Apnea Syndromes; Sleep Initiation and Maintenance Disorders; Stress, Psychological; Taurine; Topiramate; Trazodone

2015

Other Studies

1 other study(ies) available for quetiapine-fumarate and Sleep-Apnea-Syndromes

ArticleYear
Respiratory dysfunction in sleep apnea associated with quetiapine.
    Pharmacopsychiatry, 2008, Volume: 41, Issue:3

    Quetiapine is an atypical antipsychotic with good tolerability, but has recently been associated with respiratory dysfunction. The aim of this work is to report on moderate to severe respiratory dysfunction after normal oral doses of quetiapine in two obese patients with sleep apnea syndrome (SAS). In the first case, acute respiratory failure and coma occurred after a single normal oral dose of quetiapine in combination with lorazepam (although even higher doses of lorazepam alone were tolerated) in a patient with previously unknown SAS. Intensive care treatment and mechanical ventilation led to full recovery. The second case was a patient with an operated obstructive SAS in which quetiapine was associated with nocturnal respiratory dysfunction and confusion. Respiratory function should be monitored when using quetiapine in patients with possible sleep apnea, particularly in obese patients and when given in combination with benzodiazepines.

    Topics: Adolescent; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Quetiapine Fumarate; Respiration; Sleep Apnea Syndromes

2008